RG
ADMA icon

Renaissance Group’s ADMA Biologics ADMA Stock Holding History

Renaissance Group’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-642,535
Closed -$5.79M – 236
2026
Q1 		$5.79M Buy
642,535
+166,856
+35% +$2.63M 0.24% 117
2025
Q4 		$8.68M Sell
475,679
-40,909
-8% -$689K 0.35% 73
2025
Q3 		$7.57M Buy
516,588
+173,016
+50% +$2.97M 0.29% 100
2025
Q2 		$6.26M Buy
+343,572
New +$7.01M 0.24% 102

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Group's ADMA Position: Q2 2026 in Review

Renaissance Group sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 642,535 shares — an estimated $5.79M sold.

Renaissance Group first reported a position in ADMA in Q2 2025 and held it in 4 quarters. The position peaked at $8.68M in Q4 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Renaissance Group reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Renaissance Group sold 642,535 ADMA Biologics shares in Q2 2026, an estimated $5.79M.
  • Renaissance Group first reported a position in ADMA Biologics in Q2 2025 and held it in 4 quarters.
  • Renaissance Group's ADMA Biologics position peaked at $8.68M in Q4 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Renaissance Group's 13F filing for Q2 2026, filed 13 Aug 2026.